New Horizon in Materials and Photonics Research from Scientific Excellence to Industrial Impact
[1L8-3]
Research for "Rule Breaker" Drugs (High molecular weight molecules including antibody drug conjugate)
발표자안진희 (광주과학기술원)
연구책임자안진희 (광주과학기술원)
Abstract
Recently, there has been growing interest in large-molecule compounds like ADCs (Antibody-Drug Conjugates) in the development of new drugs. The advantage of ADCs lies in their ability to combine the targeting capability of antibodies with the potent cell-killing ability of chemotherapy, while minimizing damage to healthy tissues. This approach holds great promise, especially for cancers that are resistant to traditional treatments. Especially, Enhertu has demonstrated the potential of a new class of ADC drugs. ADCs consist of an antibody, a linker, and a payload. As polymeric substances, ADCs show strong anticancer effects, but improvements are still needed in terms of efficacy, toxicity, and physicochemical properties. This presentation aims to introduce current trends in ongoing research and the specific focus areas of our research group.